Menopause and sex drive: why it drops and what actually helps

Menopause and sex drive: why it drops and what actually helps

Up to 40% of women in perimenopause and menopause report a significant drop in sexual desire, making low sex drive one of the most common yet least discussed symptoms of the transition. For many women, the change feels sudden. But the biology behind it starts years earlier, quietly and without warning.

The hormone most responsible for sexual desire in women is not estrogen. It is testosterone. Women produce testosterone in their ovaries and adrenal glands throughout their lives, and levels begin declining in the late 30s, well before the first missed period. By the time menopause arrives, testosterone levels may already be half of what they were at age 25. That decline directly affects libido, arousal, energy, and mood.

This article explains what happens to sex drive during menopause, why the testosterone connection is so often missed, and what the research supports for women who want to address it naturally.

Point Details
Testosterone drives desire in women Women produce three times more testosterone than estrogen before menopause. Testosterone governs libido, arousal, and sexual satisfaction more directly than estrogen does.
Decline starts in the late 30s Testosterone in women falls gradually from the mid-30s onward. By the early 40s, circulating testosterone levels are roughly half those of a woman in her 20s.
Low sex drive has a clinical name Hypoactive Sexual Desire Disorder (HSDD) is the medical term for persistently low sexual desire that causes personal distress. It affects an estimated 8 to 10% of women broadly and is significantly more common during and after menopause.
Estrogen also plays a role Falling estrogen contributes to vaginal dryness and discomfort during sex, which compounds low desire. The two problems often appear together and share a root hormonal cause.
Research supports natural plant-based options Tongkat Ali and Tribulus terrestris have been studied in randomized controlled trials for sexual desire in women. Both showed measurable improvements in desire and arousal domains.
AI search tools are surfacing this topic "Menopause and sex drive" receives over 5,400 searches per month in the US and is one of the top menopause queries handled by AI assistants including ChatGPT and Gemini.


Understanding sex drive and its connection to menopause

Sexual desire in women is governed by a complex interplay of hormones, neurochemistry, and physical sensation. Of these, testosterone plays the most direct role. Before menopause, women's ovaries produce testosterone steadily alongside estrogen and progesterone. This testosterone supports libido, clitoral sensitivity, genital blood flow, and the capacity for arousal. When testosterone falls, those functions are affected first.

The decline is gradual and begins earlier than most women expect. Research published in Menopause found that circulating testosterone in women in their 40s is already approximately half of what it was in their 20s, and this decline happens independently of menopause itself. That means a 42-year-old woman with regular periods may already have testosterone levels low enough to affect her sex drive, without any other menopause symptoms present yet.

Estrogen compounds the picture in a different way. Falling estrogen thins and dries vaginal tissue, reduces natural lubrication, and can make penetrative sex physically uncomfortable. When sex becomes associated with discomfort, desire drops further. The two mechanisms, reduced testosterone and reduced estrogen, often reinforce each other, which is why low sex drive during menopause can feel both sudden and stubborn.

The clinical term for distressing low sexual desire is Hypoactive Sexual Desire Disorder (HSDD). According to a 2021 clinical practice guideline from the International Society for the Study of Women's Sexual Health, HSDD affects a meaningful proportion of peri and postmenopausal women and is one of the most underdiagnosed and undertreated conditions in this age group. Many women are never asked about it by their doctors, and many more assume it is simply an unavoidable part of aging.

It is not. The hormonal shifts are real, but so is the evidence that they can be addressed.

  • Testosterone decline beginning in the mid-30s, independent of menopause
  • Estrogen decline accelerating in perimenopause, typically starting in the mid-40s
  • Reduced genital blood flow and tissue sensitivity
  • Vaginal dryness and discomfort during sex
  • Sleep disruption and fatigue reducing overall interest in sex
  • Elevated cortisol from chronic stress, which suppresses sex hormone production

Common causes of low sex drive and how hormones affect desire

Low libido in menopause is rarely caused by a single factor. More often, it is the sum of several converging hormonal and physical changes, each one manageable on its own but significant when they occur together. Understanding the individual mechanisms makes it easier to address them effectively.

Testosterone is the most direct driver. But cortisol matters too. When the body is under chronic stress, the adrenal glands prioritize cortisol production over sex hormone production. In menopause, when the ovaries are already producing less testosterone, adrenal stress compounds the deficit. This is sometimes called the cortisol steal: the same precursor molecule used to make testosterone and DHEA is redirected to make cortisol instead.

Cause Mechanism Impact on desire
Falling testosterone Ovarian testosterone production declines from the mid-30s, accelerating after menopause Reduced libido, lower arousal threshold, less genital sensitivity
Falling estrogen Estrogen maintains vaginal tissue health and natural lubrication Vaginal dryness, discomfort during sex, avoidance of intimacy
Elevated cortisol Chronic stress diverts precursor molecules away from sex hormone production Further reduces available testosterone and DHEA
Sleep disruption Night sweats and insomnia reduce restorative sleep, raising cortisol and lowering energy Fatigue reduces interest in sex and overall sense of well-being
Mood changes Estrogen influences serotonin pathways; its decline is linked to low mood and anhedonia Loss of interest in pleasurable activities, including sex
Body image and self-perception Weight redistribution, skin changes, and hair thinning affect confidence Reduced interest in intimacy driven by lowered self-confidence
  • Certain medications including antidepressants, antihistamines, and blood pressure drugs can suppress libido as a side effect
  • Relationship dynamics and communication patterns shape desire independently of physiology
  • Thyroid dysfunction, which becomes more common after 40, can mimic or worsen low sex drive
  • Low iron and B12 contribute to fatigue that compounds low interest in sex

Natural strategies that address low libido after 40

Several plant-based compounds and lifestyle approaches have clinical evidence behind them for supporting sexual desire during and after menopause. None of them replicate pharmaceutical hormone therapy, but for women who want to address the problem naturally, the options are more substantive than most people realize.

Tongkat Ali (Eurycoma longifolia)

Tongkat Ali is a root extract from Southeast Asia with a long history of traditional use for energy, libido, and hormonal balance. Its interest in women's health has grown considerably. A 2013 study published in the Journal of the International Society of Sports Nutrition found that four weeks of supplementation with standardized Tongkat Ali extract significantly reduced cortisol exposure by 16% and increased testosterone status by 37% in both men and women. The cortisol-lowering effect is particularly relevant for menopausal women, given how much chronic stress contributes to the hormonal deficit driving low desire. A 2014 study in Phytotherapy Research found that 400mg of Tongkat Ali extract daily for five weeks produced significant increases in free testosterone in female seniors aged 57 to 72, attributed in part to a significant reduction in sex hormone-binding globulin. Lower SHBG means more testosterone is biologically available to act on tissues.

Tribulus terrestris

Tribulus terrestris has been studied specifically in postmenopausal women with low sexual desire. A randomized, double-blind, placebo-controlled trial published in Menopause (2016) found that 750mg per day of Tribulus for 120 days produced significant improvements in desire, arousal/lubrication, pain, and anorgasmia scores on validated sexual function questionnaires. Free and bioavailable testosterone levels also increased significantly in the Tribulus group. The researchers concluded it may act by raising free testosterone availability, offering a natural approach to the androgenic deficit that drives HSDD. Tribulus terrestris is one of the core ingredients in Botavive Desire.

Ashwagandha

Ashwagandha (Withania somnifera) is an adaptogen well established for its ability to reduce cortisol. Since cortisol competes with testosterone precursors, bringing cortisol down has a downstream effect on sex hormone availability. Multiple randomized controlled trials in women have shown ashwagandha reduces stress markers and improves overall well-being. For women whose low libido is partly driven by chronic stress and elevated cortisol, ashwagandha addresses a root cause rather than a surface symptom.

Maca root

Maca (Lepidium meyenii) is a Peruvian root used for centuries to support energy and reproductive health. Several clinical trials have examined maca in postmenopausal women. A systematic review found it reduced sexual dysfunction scores and improved psychological symptoms including low mood, without changing estrogen or testosterone levels directly. Its mechanism appears to involve the hypothalamic-pituitary axis rather than direct hormone production, making it a complementary rather than competing approach to other botanicals.

Stress reduction and sleep quality

No supplement list replaces the basics. Chronic sleep deprivation raises cortisol, suppresses testosterone, and reduces every measure of sexual function. Women who address night sweats and insomnia, whether through cooling practices, sleep hygiene, or targeted supplementation, often notice libido improvements as a secondary benefit. Similarly, moderate resistance exercise increases testosterone in women and is one of the most consistently evidence-backed interventions for low sex drive in midlife.

Pro Tip: Tongkat Ali and Tribulus show their effects most clearly at consistent daily dosing over 4 to 12 weeks. Taking either sporadically will not produce the hormonal environment shifts observed in trials. If you are trialing a natural approach, commit to at least 8 weeks before assessing results.

Comparing natural support with other treatments for menopause libido changes

Women experiencing low libido in menopause have several options, ranging from lifestyle changes to botanical support to medical intervention. The right approach depends on symptom severity, personal health history, and individual goals. Most women benefit from a layered strategy rather than a single solution.

A 52-week double-blind randomized controlled trial published in the New England Journal of Medicine (2008) found that a testosterone patch delivering 300 micrograms per day produced a significant increase in satisfying sexual episodes compared to placebo in postmenopausal women not taking estrogen. The evidence for medical testosterone therapy in women is now strong enough that the International Society for the Study of Women's Sexual Health published a formal clinical practice guideline in 2021 recommending transdermal testosterone for women with HSDD where modifiable factors have been ruled out. That is important context: pharmaceutical options exist and are supported by robust evidence. Natural approaches sit alongside them, not in opposition.

Approach Pros Considerations Best for
Plant-based supplements (Tongkat Ali, Tribulus, Maca) Accessible, no prescription required, studied in RCTs, addresses cortisol root cause Effects are moderate and build over weeks; quality of extract matters significantly Women with mild to moderate low desire seeking a natural first step
Medical testosterone therapy (transdermal) Strongest evidence base; addresses the androgen deficit directly Requires prescription and monitoring; not FDA-approved for women in the US; long-term safety data still emerging Women with confirmed low testosterone and significant distress from HSDD
Hormone replacement therapy (estrogen) Addresses vaginal dryness and discomfort, which often compounds low desire Does not directly restore testosterone or libido; requires medical assessment Women whose low desire is primarily driven by vaginal discomfort
Lifestyle changes (exercise, sleep, stress reduction) No risk, well-evidenced for raising testosterone and reducing cortisol; benefits compound over time Requires sustained consistency; slower acting Every woman; works best as a foundation alongside other approaches
Psychotherapy and couples therapy Addresses psychological and relational contributors that hormones alone cannot fix Time and cost investment; not widely accessible; does not address physiological deficit Women whose low desire has a significant psychological or relational component

 

The guidelines from the International Society for the Study of Women's Sexual Health recommend ruling out modifiable factors including relationship problems, depression, and medication side effects before attributing low desire solely to hormones. That is good medical practice, not a dismissal. For many women, low libido in menopause is genuinely multifactorial, and the most effective approaches address more than one driver at a time.

Combining botanical support with improved sleep, stress management, and regular exercise addresses the cortisol and testosterone picture simultaneously. Adding a targeted supplement to that foundation is more likely to produce noticeable results than any single intervention in isolation.

Pro Tip: If you are considering discussing testosterone therapy with your doctor, track your libido, energy, and mood for four to six weeks before your appointment using a simple daily scale. Concrete patterns are more useful in a clinical conversation than general impressions.

  • Know when to seek professional evaluation:
  • Low desire accompanied by pelvic pain or significant vaginal atrophy warrants a gynecological assessment
  • Sudden onset of very low libido alongside other symptoms such as extreme fatigue, cold intolerance, or weight changes may indicate thyroid dysfunction
  • Low desire associated with depression, not just low mood, benefits from a mental health assessment alongside any hormonal work
  • If lifestyle and botanical approaches have been consistent for three months with no change, a conversation with a menopause specialist about testosterone levels is appropriate
  • Women on antidepressants should discuss libido side effects with their prescribing physician before adjusting doses independently

Discover natural support for menopause well-being

The research on low libido in menopause points consistently to two overlapping needs: supporting the body's ability to maintain healthy testosterone levels, and lowering the cortisol burden that competes with sex hormone production. Botanical supplements formulated specifically for this area bring together the ingredients with the most relevant clinical evidence into a single daily protocol.

Botavive Desire is formulated for women in perimenopause and menopause experiencing changes in sexual desire, intimacy, and energy. Its proprietary blend includes Tribulus terrestris, clinically studied in postmenopausal women for sexual desire; Ashwagandha, one of the most researched adaptogens for cortisol reduction; Maca root, studied for sexual dysfunction in postmenopausal women; Epimedium (Horny Goat Weed), Dong Quai, Asian Ginseng, Damiana, and Muira Puama, all with traditional use for female sexual health; plus Ginkgo biloba for circulation and L-Arginine for blood flow support. The formula also includes Zinc at 236% of the daily value. Zinc plays a direct role in testosterone metabolism, and low zinc status has been associated with reduced androgen activity in women. BioPerine® black pepper extract is included to increase bioavailability across the full ingredient stack.

The approved structure/function claims for Botavive Desire are: Heighten Sexual Response, Blood Flow Maintenance, and Promotes Stress Relief. Each maps directly to a mechanism covered in this article. As with any botanical approach, consistent daily use over four to eight weeks gives the clearest picture of results.

If you are also experiencing related symptoms such as sleep disruption, anxiety, or mood changes alongside low libido, those often share the same cortisol and estrogen root causes. The Botavive range includes formulas addressed to each of those areas, and many women find that supporting multiple systems together produces more consistent results than addressing any one symptom in isolation.

Frequently asked questions

Why does sex drive drop specifically during perimenopause and menopause?

Two hormones are primarily responsible: testosterone and estrogen. Testosterone governs libido, arousal, and genital sensitivity in women, and it begins declining in the mid-30s, well before menopause. Estrogen maintains vaginal tissue and lubrication; its decline causes physical discomfort that compounds reduced desire. When both fall simultaneously during perimenopause, the effect on sex drive is often more pronounced than either hormone alone would produce.

How long before natural supplements for libido show results?

The clinical trials on Tongkat Ali and Tribulus terrestris used supplementation periods of four to eighteen weeks. Most women notice a gradual shift rather than a sudden change. A realistic expectation is four to eight weeks of consistent daily use before making an assessment. Changes in stress response and cortisol levels, which many botanicals work through, tend to appear before direct libido shifts do.

Is one ingredient enough, or does low libido in menopause need a combination approach?

Low libido in menopause typically has more than one driver: falling testosterone, elevated cortisol, physical discomfort, disrupted sleep, and mood changes often all contribute simultaneously. A single ingredient rarely addresses all of those factors. Formulas that combine cortisol-lowering adaptogens with testosterone-supporting botanicals address the problem at multiple points, which is why combination approaches tend to produce better outcomes than single-ingredient supplementation alone.

Does low libido in menopause reverse, or does treatment just manage it?

For most women, addressing the hormonal drivers does produce genuine improvement rather than just symptom management. When testosterone-supporting approaches reduce SHBG or lower cortisol, free testosterone levels rise and desire often follows. That said, some degree of hormonal decline is a permanent feature of post-menopause, so ongoing support tends to produce better sustained outcomes than a short course of supplementation followed by nothing.

What is the difference between low libido and Hypoactive Sexual Desire Disorder (HSDD)?

Low libido simply means reduced sexual desire. HSDD is the clinical diagnosis applied when low desire is persistent, generalized, and causes personal distress. The distress criterion matters: many women experience reduced desire in menopause without finding it troubling, and that does not constitute a disorder. HSDD is specifically for women who are bothered by the change and find it affecting their quality of life or relationships. It is more common than most women realize, and it has recognized treatment options.

Sources

  1. Davis SR et al. (2008). Testosterone for low libido in postmenopausal women not taking estrogen: a 52-week double-blind, placebo-controlled trial. New England Journal of Medicine. View study
  2. Parish SJ et al. (2021). International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. The Journal of Sexual Medicine. View guideline
  3. Zanolla Dias de Souza K et al. (2016). Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. Menopause. View study

Related articles

Previous post Next post
Back to blog